VERNON HILLS, Ill.--(BUSINESS WIRE)--Dec. 15, 2004-- Applied NeuroSolutions, Inc. (OTCBB:APNS) (www.appliedneurosolutions.com), headquartered here, said today it signed a non-exclusive agreement with bioMerieux, S.A. (Euronext: FR0010096479 - BIM) with the aim of bringing to market on a worldwide basis what is expected to be the first definitive biologic test for the diagnosis of Alzheimer's disease ("AD").